Abstract

Triggering receptor expressed on myeloid cells-2 (TREM2) and colony-stimulating factor 1 receptor (CSF1R) are crucial molecules for microgliopathy, which is characterized by microglia dysfunction and has recently been proposed as the neuropathological hallmark of neurological disorders. TREM2 and CSF1R are receptors expressed primarily in microglia in the brain and modulate microglial activation and survival. They are thought to be in close physical proximity. However, whether there is a direct interaction between these receptors remains elusive. Moreover, the physiological role and mechanism of the interaction of TREM2 and CSF1R remain to be determined. Here, we found that TREM2 interacted with CSF1R based on a co-immunoprecipitation assay. Additionally, we found that CSF1R knockdown significantly reduced the survival of primary microglia and increased the Trem2 mRNA level. In contrast, CSF1R expression was increased in Trem2-deficient microglia. Interestingly, administration of CSF1, the ligand of CSF1R, partially restored the survival of Trem2-deficient microglia in vitro and in vivo. Furthermore, CSF1 ameliorated Aβ plaques deposition in Trem2-/-; 5XFAD mouse brain. These findings provide solid evidence that TREM2 and CSF1R have intrinsic abilities to form complexes and mutually modulate their expression. These findings also indicate the potential role of CSF1 in therapeutic intervention in TREM2 variant-bearing patients with a high risk of Alzheimer’s disease (AD).

Highlights

  • Triggering receptor expressed on myeloid cells-2 (TREM2), an immunomodulatory receptor dominantly expressed in myeloid lineage cells such as dendritic cells, osteoclasts and microglia, is essential in activation and survival of myeloid cells

  • It has been proposed that TREM2 and Colony stimulating factor 1 receptor (CSF1R) are in close physical proximity [6]

  • We found that full-length TREM2 did not interact with the CSF1R amino-terminal fragment

Read more

Summary

Introduction

Triggering receptor expressed on myeloid cells-2 (TREM2), an immunomodulatory receptor dominantly expressed in myeloid lineage cells such as dendritic cells, osteoclasts and microglia, is essential in activation and survival of myeloid cells. The genetic variants of TREM2 result in an increased risk of several neurodegenerative disorders, including Alzheimer’s disease (AD) [1,2,3,4,5]. Studies have revealed that people with CSF1R variants bear an adult-onset neurodegenerative disorder characterized by dementia and motor impairments, named adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) [12, 13]. TREM2 and CSF1R are considered crucial molecules for “microgliopathy”, which is characterized by reactive gliosis and microglia dysfunction and has been recently proposed as the neuropathological hallmark of neurological disorders [5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call